Clinical Trial Update: Efficacy of CC-5013 (Revlimid or Lenalidomide) in Patients With Primary Systemic Amyloidosis [Phase 2]

View source ↗

Summary

Phase 2 trial update reporting efficacy results for lenalidomide (Revlimid) in patients with AL amyloidosis (primary systemic amyloidosis).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Al Amyloidosis

Drugs mentioned

• Revlimid (lenalidomide)

Snippet

Sponsor: Mayo Clinic | Conditions: Amyloidosis | Phase 2 | Status: COMPLETED